These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 39365581)

  • 1. Variation in Opioid Agonist Dosing in Clinical Trials by Race and Ethnicity.
    Ross RK; Inose S; Shulman M; Nunes EV; Zalla LC; Burlew AK; Rudolph KE
    JAMA Netw Open; 2024 Oct; 7(10):e2436612. PubMed ID: 39365581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Racial and Ethnic Disparities in the Use of Medication to Treat Opioid Use Disorder Among Pregnant Women in Massachusetts.
    Schiff DM; Nielsen T; Hoeppner BB; Terplan M; Hansen H; Bernson D; Diop H; Bharel M; Krans EE; Selk S; Kelly JF; Wilens TE; Taveras EM
    JAMA Netw Open; 2020 May; 3(5):e205734. PubMed ID: 32453384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Racial and Ethnic Inequities in Buprenorphine and Methadone Utilization Among Reproductive-Age Women with Opioid Use Disorder: an Analysis of Multi-state Medicaid Claims in the USA.
    Xu KY; Schiff DM; Jones HE; Martin CE; Kelly JC; Bierut LJ; Carter EB; Grucza RA
    J Gen Intern Med; 2023 Dec; 38(16):3499-3508. PubMed ID: 37436568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Racial/Ethnic Segregation With Treatment Capacity for Opioid Use Disorder in Counties in the United States.
    Goedel WC; Shapiro A; Cerdá M; Tsai JW; Hadland SE; Marshall BDL
    JAMA Netw Open; 2020 Apr; 3(4):e203711. PubMed ID: 32320038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the delivery of medications for opioid use disorder during hospitalization by racial categories: A retrospective cohort analysis.
    Priest KC; King CA; Englander H; Lovejoy TI; McCarty D
    Subst Abus; 2022; 43(1):1251-1259. PubMed ID: 35670778
    [No Abstract]   [Full Text] [Related]  

  • 6. Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults.
    Jaffe K; Slat S; Chen L; Macleod C; Bohnert A; Lagisetty P
    J Subst Use Addict Treat; 2024 Aug; 163():209361. PubMed ID: 38703949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder.
    Schiff DM; Nielsen TC; Hoeppner BB; Terplan M; Hadland SE; Bernson D; Greenfield SF; Bernstein J; Bharel M; Reddy J; Taveras EM; Kelly JF; Wilens TE
    Am J Obstet Gynecol; 2021 Oct; 225(4):424.e1-424.e12. PubMed ID: 33845029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Racial Inequality in Receipt of Medications for Opioid Use Disorder.
    Barnett ML; Meara E; Lewinson T; Hardy B; Chyn D; Onsando M; Huskamp HA; Mehrotra A; Morden NE
    N Engl J Med; 2023 May; 388(19):1779-1789. PubMed ID: 37163624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
    Wakeman SE; Larochelle MR; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
    JAMA Netw Open; 2020 Feb; 3(2):e1920622. PubMed ID: 32022884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receipt of Timely Addiction Treatment and Association of Early Medication Treatment With Retention in Care Among Youths With Opioid Use Disorder.
    Hadland SE; Bagley SM; Rodean J; Silverstein M; Levy S; Larochelle MR; Samet JH; Zima BT
    JAMA Pediatr; 2018 Nov; 172(11):1029-1037. PubMed ID: 30208470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City.
    Hansen H; Siegel C; Wanderling J; DiRocco D
    Drug Alcohol Depend; 2016 Jul; 164():14-21. PubMed ID: 27179822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Daily Doses of Buprenorphine With Urgent Health Care Utilization.
    Axeen S; Pacula RL; Merlin JS; Gordon AJ; Stein BD
    JAMA Netw Open; 2024 Sep; 7(9):e2435478. PubMed ID: 39320889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are gaps in rates of retention on buprenorphine for treatment of opioid use disorder closing among veterans across different races and ethnicities? A retrospective cohort study.
    Hayes CJ; Raciborski RA; Martin BC; Gordon AJ; Hudson TJ; Brown CC; Pro G; Cucciare MA
    J Subst Use Addict Treat; 2024 Nov; 166():209461. PubMed ID: 39067770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Hospital Adoption of an Emergency Department Treatment Pathway for Opioid Use Disorder and Patient Initiation of Buprenorphine After Discharge.
    Solomon KT; O'Connor J; Gibbons JB; Kilaru AS; Feder KA; Xue L; Saloner B; Stuart EA; Cole ES; Hulsey E; Meisel Z; Patel E; Donohue JM
    JAMA Health Forum; 2023 Mar; 4(3):e230245. PubMed ID: 36961457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of Web-Based Single-Session Empowered Relief in Patients With Chronic Pain Taking Methadone or Buprenorphine: Protocol for a Single-Arm Trial.
    Klein MR; Darnall BD; You DS
    JMIR Res Protoc; 2024 Jun; 13():e53784. PubMed ID: 38843513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014.
    Hadland SE; Wharam JF; Schuster MA; Zhang F; Samet JH; Larochelle MR
    JAMA Pediatr; 2017 Aug; 171(8):747-755. PubMed ID: 28628701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine.
    Farnum SO; Makarenko I; Madden L; Mazhnaya A; Marcus R; Prokhorova T; Bojko MJ; Rozanova J; Dvoriak S; Islam Z; Altice FL
    Addiction; 2021 Jan; 116(1):83-93. PubMed ID: 32428276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Racial/ethnic disparities in timely receipt of buprenorphine among Medicare disability beneficiaries.
    Miles J; Treitler P; Hermida R; Nyaku AN; Simon K; Gupta S; Crystal S; Samples H
    Drug Alcohol Depend; 2023 Nov; 252():110963. PubMed ID: 37748421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
    Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
    Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescribing practices in opioid agonist treatment and changes in compliance to clinical dosing guidelines in British Columbia, Canada.
    Guerra-Alejos BC; Yan Y; Kurz M; Mudalige N; Min JE; Homayra F; Nosyk B
    Addiction; 2024 Aug; 119(8):1453-1459. PubMed ID: 38584294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.